Krsnaa Diagnostics Limited has informed the Exchange about General Updates
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 0.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics' wholly owned subsidiary, Krsnaa Retail Private Limited (KRPL), has acquired an additional 16% equity stake in Apulki Healthcare (KDMC) Private Limited, raising its total holding in the entity to 26%. Apulki Healthcare runs hospitals focused on oncology and cardiology and was incorporated in October 2024 with nil turnover so far. The acquisition was done for a cash consideration of just INR 16,000, with no related party involvement and no government approvals needed. This is a follow-up to a December 2024 disclosure when an initial stake was acquired, suggesting KRPL is steadily building control in this hospital-focused entity.
Krsnaa Diagnostics is diversifying beyond its core diagnostics business into hospital operations in cancer and cardiac care through its subsidiary. The tiny acquisition cost (INR 16,000) signals an early-stage, strategic build-up rather than a large transformative deal, so near-term stock impact is likely limited but the move could matter if the hospital project scales meaningfully.